IDEXX Laboratories (IDXX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

IDEXX Laboratories

NasdaqGS•Healthcare•Diagnostics & Research

$506.48-7.14(-0.01%)After hours

Market Cap

$39.83B

P/E

34.9x

P/S

8.7x

P/B

24.7x

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

How this company scores

ExcellentMetricSide Score: 94/100

Strongest: Profitability (25/25); weakest: Cash & Earnings Quality (23/25).

Profitability25/25

Growth23/25

Balance Sheet & Red Flags23/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowStrong marginsHigh ROERising earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 34.9x5y range 34.9x – 75.3x

Currently below its 20-quarter median.

P/S · 8.7x5y range 8.3x – 17.4x

Currently near its 20-quarter median.

P/B · 24.7x5y range 21.2x – 81.3x

Price & Volume

Market Cap $39.83B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.55B
Q. Revenue: $1.22B
TTM EBITDA: $1.61B
TTM Op. Income: $1.46B
Q. Op. Income: $425.57M
TTM Net Income: $1.14B
Q. Net Income: $338.41M
EPS: $4.29
Shares Out.: $78.95M

$4.55B in TTM revenue grew 12.8% YoY, reaching $1.22B last quarter. TTM EBITDA of $1.61B and TTM operating income of $1.46B show growth is flowing through to the bottom line. TTM net income of $1.14B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.0%
EBITDA Margin: 38.4%
Op. Margin: 35.0%
Net Margin: 27.8%

Op. margin of 35.0% is up 1.4% YoY — cost efficiency is improving. Net margin at 27.8% and gross margin of 64.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 34.9x
P/S Ratio: 8.7x
P/B Ratio: 24.7x

At 34.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 8.7x and P/B of 24.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.44B
Cash: $196.93M
Long-Term Debt: $299.87M
Book Value: $1.61B
D/E Ratio: 0.2
Debt/EBITDA: 0.6

With $3.44B in assets and $299.87M in long-term debt, D/E is 0.2and book value is $1.61B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 5 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $347.16M
TTM Free Cash Flow: $1.25B
FCF Margin: 27.5%
FCF / Net Income: 1.1

TTM FCF of $1.25B on $347.16M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.